India's Glenmark to study potential Covid-19 drug combination
The study will look to enroll 158 hospitalized patients of moderate Covid-19 in India
Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir - as a potential Covid-19 treatment.
The study will look to enroll 158 hospitalized patients of moderate Covid-19 in India, the company added.
Last month, Glenmark said it would conduct clinical trials in India of just favipiravir as a potential treatment for Covid-19.
Keep updated, follow The Business Standard's Google news channel
